文献速递复苏、休克与脓毒症

2024年静脉输液短缺期间术中标准液体实践的变化

Standard Intraoperative Fluid Practices During the 2024 Intravenous Fluid Shortage.
PubMed 文献 · JAMA Netw Open · 2026-09-01
一句话结论2024年输液短缺期间,大幅减少术中晶体液输注与尿量降低、导尿管使用减少和再入院减少相关,且未增加术中低血压、术后急性肾损伤或费用。

实施减少液体方案与术中晶体液输注降低75.2%相关(校正eβ 0.25,95%CI 0.24-0.26,P<.001),同时尿量降低(校正eβ 0.91,95%CI 0.85-0.96,P=.002)、导尿管使用减少(ARR 0.87,95%CI 0.83-0.92,P<.001)和再入院减少(ARR 0.82,95%CI 0.75-0.89,P<.001)。术中低血压、术后急性肾损伤和费用无显著差异。结果挑战了标准术中液体实践。

要点

  • 术中晶体液输注大幅减少75.2%(校正eβ 0.25,95%CI 0.24-0.26,P<.001),未增加术中低血压(校正eβ 1.01,95%CI 1.00-1.02,P=.07)。
  • 减少液体方案与术后急性肾损伤无显著差异(ARR 0.97,95%CI 0.86-1.09,P=.58),与费用无显著差异(校正eβ 1.00,95%CI 0.98-1.01,P=.46)。
  • 尿量降低(校正eβ 0.91,95%CI 0.85-0.96,P=.002),但导尿管使用减少(ARR 0.87,95%CI 0.83-0.92,P<.001)和再入院减少(ARR 0.82,95%CI 0.75-0.89,P<.001)。
  • 该研究为回顾性自然实验,不能直接外推为所有手术人群的通用液体管理推荐。

适用人群与场景

  • 成人手术患者,来自纽约布朗克斯9家不同级别医院,研究期间2024年9月2日至12月31日。
  • 原文未提及具体手术类型、排除标准或急诊/ICU场景。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。
  • 干预为医院层面实施的减少术中静脉晶体液输注的方案。
  • 实施后术中晶体液输注较前降低75.2%(校正eβ 0.25,95%CI 0.24-0.26,P<.001)。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 干预:医院层面减少术中静脉晶体液输注的方案;对照:实施前时段。
  • 主要结果:术中晶体液输注降低75.2%(校正eβ 0.25,95%CI 0.24-0.26,P<.001)。
  • 次要结果:尿量降低(校正eβ 0.91,95%CI 0.85-0.96,P=.002)、导尿管使用减少(ARR 0.87,95%CI 0.83-0.92,P<.001)、再入院减少(ARR 0.82,95%CI 0.75-0.89,P<.001)。
  • 不良事件/安全性:术中低血压(校正eβ 1.01,95%CI 1.00-1.02,P=.07)、术后急性肾损伤(ARR 0.97,95%CI 0.86-1.09,P=.58)、费用(校正eβ 1.00,95%CI 0.98-1.01,P=.46)无显著差异。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(自然实验),非随机对照试验。
  • 局限:回顾性设计、单医院网络(9家医院)、无随机化、可能存在混杂偏倚,原文未给出证据等级或推荐强度。

对床旁实践的改变

  • 在术中液体管理上,可考虑减少晶体液输注而不增加术中低血压、术后急性肾损伤或费用,但需结合患者个体情况。
  • 减少液体方案可能与尿量降低相关,但导尿管使用和再入院减少,提示可减少不必要的导尿。
  • 该结果来自回顾性自然实验,不能直接推广为所有手术患者的通用方案,尤其不适用于原文未提及的特殊人群(如急诊、ICU、特定手术类型)。
  • 常见陷阱:将观察性关联误认为因果推荐,或忽视尿量降低的潜在风险。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: A nationwide intravenous fluid shortage in 2024 prompted hospitals to substantially reduce intraoperative crystalloid administration, creating a natural experiment to examine standard intraoperative fluid practices. The clinical consequences of such abrupt reductions in fluid use remain unclear.

OBJECTIVE: To evaluate the associations among a marked reduction in intraoperative crystalloid administration, perioperative outcomes, and costs of care.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted from September 2 to December 31, 2024, across a hospital network in the Bronx, New York, comprising adults undergoing surgery at 9 hospitals of different acuity levels.

EXPOSURE: The exposure was the implementation of a hospital-wide intervention aimed at reducing intraoperative intravenous crystalloid administration.

MAIN OUTCOMES AND MEASURES: Primary outcomes included change in intraoperative crystalloid administration. Additional outcomes included intraoperative hypotension, urine output, urinary catheter utilization, hospital readmissions, postoperative acute kidney injury, length of stay, and costs of care.

RESULTS: A total of 38 976 patients (mean [SD], age 55.7 [19.8] years; 21 944 [56.3%] female), including 12 026 (30.9%) before and 26 950 (69.1%) during implementation of a fluid reduction bundle, were included in the study. The implementation of the fluid reduction bundle was associated with a 75.2% lower intraoperative crystalloid administration (adjusted exponentiated β coefficient [eβ], 0.25; 95% CI, 0.24-0.26; P < .001). The intervention was associated with lower urine output (adjusted eβ, 0.91; 95% CI, 0.85-0.96; P = .002), reduced urinary catheter utilization (adjusted relative risk [ARR], 0.87; 95% CI, 0.83-0.92; P < .001), and fewer hospital readmissions (ARR, 0.82; 95% CI, 0.75-0.89; P < .001). There were no meaningful differences in intraoperative hypotension (adjusted eβ, 1.01; 95% CI, 1.00-1.02; P = .07), postoperative acute kidney injury (ARR, 0.97; 95% CI, 0.86-1.09; P = .58), or costs of care (adjusted eβ, 1.00; 95% CI, 0.98-1.01; P = .46).

CONCLUSIONS AND RELEVANCE: In this cohort study's natural experiment, grossly reduced intraoperative crystalloid fluid administration was associated with lower urine output, reduced urinary catheter use, and fewer hospital readmissions, without worse patient-centered outcomes. These results challenge standard intraoperative fluid practices.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Hopstein N, Borngaesser F, Droege L, et al. Standard Intraoperative Fluid Practices During the 2024 Intravenous Fluid Shortage. JAMA Netw Open. 2026. PMID: 42742938. doi:10.1001/jamanetworkopen.2026.34064

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。